期刊文献+

多表位肿瘤疫苗的研究进展 被引量:1

Advances in multi-epitope vaccines
原文传递
导出
摘要 多表位疫苗是指同时携带多个与目标抗原相关的表位以及辅助性表位的疫苗。因其在细胞免疫方面的独特优势,已成为肿瘤疫苗研究领域的热点之一。随着分子生物学及免疫学等学科的飞速发展,使得多表位疫苗的临床应用也有了很大的进展。本文主要对多表位疫苗的选择、设计及临床应用等方面作一综述。 Multi-epitope vaccine, which carries several adjuvant epitopes and more than one epitope related to targeted antigens, has become one of the hotspots in the field of cancer vaccine development because of its unique advantages in cellular immunity. With the rapid development of molecular biology and immunology, the clinical application of muhi-epitope vaccine has made great progress. In this paper, the choice, design and clinical application of multi-epitope vaccine were reviewed.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2012年第10期588-593,共6页 Chinese Journal of New Drugs and Clinical Remedies
关键词 多表位疫苗 癌症疫苗 免疫疗法 主动 分子生物学 multi-epitope vaccine cancer vaccines immunotherapy, active molecular biology
  • 相关文献

参考文献41

  • 1YANG JM, PENG ZH, SI SH, et 01. KAll gene suppresses invasion and metastasis of hepatocellular carcinoma MHCC97-H cells in vitro and in animal models[J]. Liver International, 2008, 28( 1): 132-139.
  • 2MAC KIEWICZ J, MACKIEWCZ A. Design of clinical trials for therapeutic cancer vaccines development [J]. Eur J Pharmacol, 2009, 625(1-3): 84-89.
  • 3RAY S, CHHABRA A, MEHROTRA S. Obstacles to and opportunities for more effective peptide-bssed therapeutic immunization in human melanoma[J]. Clin Dennatol, 2009, 27 (6): 603-613.
  • 4MEYER D, TORRES JV. Hypervariable epitope construct: a synthetic immunogen that overcomes MHC restriction of antigen presentation[J]. Mol Immunol, 1999, 36( 10): 631-637.
  • 5JIANG L, ZHOU JM, YIN Y, et ol. Selection and identifcation of B-cell epitope on NS 1 protein of dengue virus type 2[J]. Virus Res, 2010, 150( 1 ): 49-55.
  • 6MALHOTRA U, NOUN J, HORTON H, et ol, Functional properties and epitope characteristics of T -cells recognizing natural HIV -1 variants[J]. Vaccine, 2009, 27 ( 48): 6678-6687.
  • 7王艳华,张德林,殷宏,付宝权.抗原表位预测方法的研究进展[J].中国兽医科学,2009,39(10):938-940. 被引量:19
  • 8周艳君,田志军,刘金霞,安同庆,彭金美,薛强,蔡雪辉,于海,李国新,刘娣,童光志,王云峰,王玫.猪繁殖与呼吸综合征病毒M蛋白B细胞抗原表位的鉴定[J].中国预防兽医学报,2009,31(4):251-255. 被引量:7
  • 9KAU R M, CHUG H, SNGH H, et 01. Identification and characterization 0 f immunodominant B-cell epitope of the C?terminus of protective antigen of Bacillus anthracis[J]. Mol Immunol, 2009, 46 ( 10): 2107-2115.
  • 10YU X, BARMINA 0, BURGOON M, et aI. Identification of measles virus epitopes using an ultra-fast method of panning phage-displayed random peptide libraries[J]. J Viro Metho, 2009, 156 (1-2): 169-173.

二级参考文献161

共引文献63

同被引文献22

  • 1GROSS- GOUPIL M, MASSARD C, RAVAUD A. Targeted therapies in metastatic renal cell carcinoma: overview of the past year[J]. Curr Urol Rep, 2012, 13(1): 16-23.
  • 2CARMICHAEL C, LAU C, JOSEPHSON DY, et al. Compre- hensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma[J]. Clin Adv Hematol Oncol, 2012, 10(5) : 307-314.
  • 3POSADAS EM, FIGLIN RA. Systemic therapy in renal cell carcinoma : advancing paradigms[J]. Oncology (Williston Park), 2012, 26(3): 290-301.
  • 4CHO IC, CHUNG J. Currrent status of targeted therapy for advanced renal cell carcinoma[J]. Korean J Urol, 2012, 23 (4): 217-228.
  • 5ESCUDIER B, GORE M. Axitinib for the management of metastatic renal cell carcinoma[J]. Drugs R D, 2011 (2): 113- 126.
  • 6RUGO HS, HERBST RS, LIA G, et ol. Phase I trial of the oral antiagiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results[J]. J Clin Oncol, 2005, 23(24): 5457-5483.
  • 7HO TH, JONASCH E. Axitinib in the treatment of metastatic renal cell carcinoma[J]. Future Oncol, 2011, 7 ( 11 ) : 1247-1253.
  • 8RIXE O, BUKOWSKI RM, MICHAELSON MD, et ol. Axitinib treatment in patients with eytokine- refractory metastatic renal- cell cancer: a phase lI study[J]. Lancet Oncol, 2007, 8 (1): 975-984.
  • 9RINI BI, WILDING G, HUDES G, et ol. Phase l/ study of axitinib in sorafenib-refraetory metastatic renal cell carcinoma[J]. J Clin Oncol, 2009, 27(27): 4462-4468.
  • 10TOMITA Y, UEMURA H, FUJIMOTO H, et al. Key predictive factors of axitinib (AG - 013736) - induced proteinuria and efficacy: a phase 11 study in Japanese patients with cytokine- refractory metastatic renal cell carcinoma[J]. Eur J Cancer, 2011, 47(17) : 2592-2602.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部